Advertisement

Topics

Search Results for "Benzodiazepine Multiple Sclerosis"

15:33 EDT 30th June 2016 | BioPortfolio

Matching Channels

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...

Systemic Sclerosis

Amyotrophic lateral sclerosis ALS

Diffuse mesangial sclerosis

B lymphocyte stimulator BlyS

Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.

Matching News

[Articles] Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

The anti-inflammatory effects of fingolimod did not slow disease progression in primary progressive multiple sclerosis. Therapeutic strategies for primary progressive multiple sclerosis might need dif...

Roche’s New Multiple Sclerosis Drug Set for Early FDA Approval

Roche’s Ocrevus (ocrelizumab) has been granted a priority review by the FDA as a treatment for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

Mutation for rare form of multiple sclerosis could be 'genetic smoking gun'

A gene variant has been linked to early onset multiple sclerosis in a small number of cases, lending weight to the hypothesis that genetic factors underlie multiple sclerosis more widely...

Consortium of Multiple Sclerosis Centers Publishes Rehab Primer

HACKENSACK, NJ -- The Consortium of Multiple Sclerosis Centers (CMSC), in collaboration with The France Foundation (TFF) and Nurse Practitioner Alternatives (NPA), has produced a Rehabilitation Primer...

[Comment] Primary progressive multiple sclerosis—why we are failing

In The Lancet, Fred Lublin and colleagues1 report negative results of a randomised, double-blind trial (INFORMS) assessing the efficacy of fingolimod, an oral sphingosine 1-phosphate receptor (S1PR) m...

Children with and without multiple sclerosis have differences in gut bacteria

In a recent study, children with multiple sclerosis had differences in the abundance of specific gut bacteria than children without the disease. Certain types of bacteria were either more or less abun...

Multiple sclerosis: Plant peptide could prevent onset of the disease

A crucial development has been made in the treatment of Multiple Sclerosis (MS). A research team has demonstrated in an animal model that, following treatment with a specially synthesized plant peptid...

Predicting who will develop multiple sclerosis

(Brigham and Women's Hospital) A team of investigators has launched a study of individuals at risk for multiple sclerosis (MS) to better understand the sequence of events that leads some people to dev...

Matching PubMed Articles

Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.

To date, there are no available factors to predict the outcome after multiple sclerosis relapse.

Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database.

Data are limited for mortality and comorbidities in patients with multiple sclerosis (MS).

Impact of multiple sclerosis on employment and use of job-retention strategies: The situation in France in 2015.

The main objective of this survey of persons with multiple sclerosis was to describe their employment situation. Secondary objectives were to ascertain when and how multiple sclerosis symptoms first i...

Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression.

Cognitive impairment occurs from the early phases of multiple sclerosis (MS), and more frequently affects secondary progressive (SP) subjects than relapsing-remitting (RR).

Genetic analysis of the isolated Faroe Islands reveals SORCS3 as a potential multiple sclerosis risk gene.

In search of the missing heritability in multiple sclerosis (MS), additional approaches adding to the genetic discoveries of large genome-wide association studies are warranted.

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement